|Articles|December 22, 2010

Novartis completes Alcon acquisition.

Novartis has agreed to purchase the remaining 23% of their share in Alcon for $168 per share.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.


Latest CME